Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04753164 · ClinicalTrials.gov registry record · Phase 2
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT04753164 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT04753164, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
Interventions
- DRUG Placebo
- DRUG ACT-539313
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04753164
The ClinicalTrials.gov registry entry for NCT04753164 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04753164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04753164 about?
NCT04753164 is a clinical study titled "Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder". Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
What is the current status of trial NCT04753164?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2021-02-16. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT04753164?
The interventions under investigation include: Placebo (DRUG), ACT-539313 (DRUG).
Who is sponsoring clinical trial NCT04753164?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.